Research detection kit NG223010516

geneticchemotherapeutic-related geneSNP

The selectivity of chemotherapy drugs is relatively weak, as they not only kill cancer cells but also damage normal cells in the body, resulting in adverse drug reactions. The effectiveness of chemotherapy is influenced by individual patient differences, including sensitivity and tolerance to chemotherapy drugs, as well as the inherent toxicity of the drugs themselves. For example, certain genetic polymorphisms in the gene encoding for UGT1A1 can result in a decreased level of glucuronidation of the active metabolite of irinotecan, resulting in accumulation of the drug and increased risk for toxicity. Nowadays, genetic testing can be used to predict individual responses to specific drugs, assisting patients in selecting appropriate chemotherapy drugs, predicting treatment efficacy, and avoiding serious side effects." DETECTED GENES This test kit enables detection of 26 target genes and 33 loci, providing guidance for the evaluation of the efficacy and adverse effects of 19 first-line chemotherapy drug combinations, including toxic side effects. DETECTION SIGNIFICANCE By detecting chemotherapeutic drug-related genes in cancer patients, it is possible to determine the sensitivity and toxicity of chemotherapy drugs. This can provide a scientific basis for predicting the efficacy of drugs, improving the specificity of treatment, reducing the risk of toxicity, and offering guidance for clinical medication. FEATURES & ADVANTAGES Ease of Use: Based on the independent patent technology RingCap®, Library preparation in 2 steps.